We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development
News

XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development

XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development
News

XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "XOMA and Schering-Plough Establish Collaboration for Therapeutic Antibody Discovery and Development "

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

XOMA Ltd. has announced the formation of collaboration with Schering-Plough Corporation, through its research and development arm, Schering-Plough Research Institute (SPRI), for therapeutic monoclonal antibody discovery and development.

The collaboration is intended to capitalize on XOMA's comprehensive antibody discovery, development and production technologies and expertise.

Under the agreement, Schering-Plough will make up-front and milestone payments to XOMA, fund XOMA's R&D activities related to the agreement, and pay royalties to XOMA on sales of products resulting from the collaboration.

Using its extensive collection of phage display libraries and optimization technologies, XOMA will discover therapeutic antibodies against one or more targets selected by SPRI.

XOMA may also utilize its proprietary Human Engineering™ technology to humanize antibody candidates generated by hybridoma techniques.

Other XOMA activities will include pre-clinical studies to support regulatory filings, cell line and process development, and production of antibodies for initial clinical trials.

"With our collective capabilities and expertise, we plan to accelerate the discovery and development of therapeutic antibodies that meet or exceed key medical and commercial design objectives," said John L. Castello, President, Chairman and Chief Executive Officer of XOMA. "We look forward to working together with Schering-Plough."

Advertisement